Lowest Debt-to-Capital Ratio in the Biotechnology Industry Detected in Shares of Osiris Therapeutics (OSIR, BTX, NBIX, NVAX, ARWR)
Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.
Osiris Therapeutics ranks lowest with a a Debt-to-Capital ratio of 0.1%. Following is Biotime with a a Debt-to-Capital ratio of 0.1%. Neurocrine Biosciences ranks third lowest with a a Debt-to-Capital ratio of 0.1%.
Novavax follows with a a Debt-to-Capital ratio of 0.1%, and Arrowhead Research rounds out the bottom five with a a Debt-to-Capital ratio of 0.6%.
SmarTrend is monitoring the recent change of momentum in Neurocrine Biosciences. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Neurocrine Biosciences in search of a potential trend change.
Keywords: lowest debt-to-capital ratio osiris therapeutics biotime neurocrine biosciences Novavax arrowhead research